Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials (Q37573815)

21 August 2017

1 reference

title

Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials (English)

1 reference

21 August 2017

1

1 reference

Lucienne Juillerat-Jeanneret

21 August 2017

series ordinal

2

object named as

Lucienne Juillerat-Jeanneret

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Therapeutic Targets

21 August 2017

published in

1 reference

21 August 2017

volume

13

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1069-1084

1 reference

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin-Darby canine kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Heterodimerization of endothelin-converting enzyme-1 isoforms regulates the subcellular distribution of this metalloprotease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

In vitro enzymatic processing of radiolabelled big ET-1 in human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-1 stimulates c-fos mRNA expression in C6 glioma cells via MAP kinase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Atrasentan: targeting the endothelin axis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Molecular characterization of a novel human endothelin receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Novel endothelin B receptor transcripts with the potential of generating a new receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin receptor antagonists inhibit endothelin in human skin microcirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Role of endothelin in the increased vascular tone of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Bosentan therapy for portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

A randomised, controlled trial of bosentan in severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Modulation of human colon tumor-stromal interactions by the endothelin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

The endothelin system in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-1: a multifunctional molecule in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelins in breast tumour cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin receptors as novel targets in tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin receptor antagonists in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Cellular and molecular mechanisms of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

TGF-beta, Smad3 and the process of progressive fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Role of endothelin in fibrosis and anti-fibrotic potential of bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelium-derived factors as paracrine mediators of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Endothelin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903074570

10.1517/14728220903074570

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference